Share on StockTwits
 

Roth Capital started coverage on shares of ANI Pharmaceuticals (NASDAQ:ANIP) in a research note issued on Tuesday, TheFlyOnTheWall.com reports. The firm set a “buy” rating and a $27.00 price target on the stock. Roth Capital’s price target would suggest a potential upside of 29.43% from the company’s current price.

Shares of ANI Pharmaceuticals (NASDAQ:ANIP) traded down 0.81% during mid-day trading on Tuesday, hitting $20.86. The stock had a trading volume of 91,548 shares. ANI Pharmaceuticals has a 52 week low of $4.80 and a 52 week high of $23.00. The stock has a 50-day moving average of $16.13 and a 200-day moving average of $10.27. The company’s market cap is $197.8 million.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings data on Thursday, November 7th. The company reported $0.16 EPS for the quarter.

ANI Pharmaceuticals, Inc, formerly BioSante Pharmaceuticals, Inc, is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.